PDI, Inc. and Transgenomic, Inc. Partner to Commercialize Personalized Medicine Molecular Diagnostic Test

    PDI, Inc. and Transgenomic, Inc. Partner to Commercialize Personalized
                      Medicine Molecular Diagnostic Test

- Companies enter long-term collaboration advancing test designed for at-risk
cardiac patients -

- PDI to host conference call today at 9:00AM ET -

PR Newswire

PARSIPPANY, N.J. and OMAHA, Neb., Oct. 15, 2013

PARSIPPANY, N.J. and OMAHA, Neb., Oct. 15, 2013 /PRNewswire/ --PDI, Inc.
(Nasdaq: PDII) and Transgenomic, Inc. (OTCBB: TBIO), today announced the
signing of a U.S. collaboration agreement to commercialize CardioPredict™, a
molecular diagnostic test developed by Transgenomic. CardioPredict™ is a
broad-based genetic assay which identifies a patient's specific genes that
influence the effectiveness and safety of many commonly used cardiovascular
drugs.

The collaboration was formed to leverage the fast-growing pharmacogenetic
testing segment that has exhibited significant expansion over the last several
years, particularly in the cardiovascular therapeutic area. Pharmacogenetic
tests identify genetic variations that affect drug effectiveness and, as such,
assist physicians with drug selection and dosing decisions. The CardioPredict™
personalized medicine test is well-positioned as the most comprehensive assay
that captures a specific set of genes known to influence each individual
patient's ability to metabolize commonly used cardiovascular drugs.

Under the terms of the strategic collaboration agreement, PDI will be
responsible for all U.S.-based marketing and promotion of CardioPredict™,
while Transgenomic will be responsible for processing CardioPredict™ in its
state-of-the-art CLIA lab and all customer support. Both parties will bear the
cost of their respective expenses and will split profit on a formula basis. In
addition, PDI will provide Transgenomic with funding support, principally to
mitigate working capital requirements. Other financial terms of the
collaboration were not disclosed.

"This collaboration with Transgenomic is another step in our pursuit of
commercialization opportunities for clinically valuable products aimed at
adding more predictable, higher growth, higher margin businesses that can
leverage the substantial full commercialization capabilities of PDI," said
Nancy Lurker, chief executive officer of PDI, Inc. "Transgenomic has strong
scientific capabilities, an established, efficient and effective CLIA lab and
superior patient/physician support infrastructure."

"CardioPredict™ is another example of our commitment to developing molecular
diagnostics that support the advancement of personalized medicine," said Paul
Kinnon, president and chief executive officer of Transgenomic, Inc. "This type
of test panel has become a preferred tool for cardiologists to personalize
therapy selection for their patients with heart disease. When launched later
this month, we believe that CardioPredict™ will be the most comprehensive
cardiology panel on the market. With an experienced sales team and a
demonstrated record of success in sales and marketing in the life sciences,
PDI is the right partner for the launch and long-term growth of
CardioPredict™. We believe that strategic partnerships such as this one will
allow Transgenomic to globally commercialize our novel assays and clinical
tests in order to more effectively address the expanding genetics market."

Lurker continued, "CardioPredict™ provides an advanced personalized
cardiovascular solution to patients who are taking one or more commonly
prescribed cardiovascular drugs in helping them and their physicians better
assess how they individually metabolize and respond to these drugs. Relative
to higher-risk cardiovascular patients being treated within several critical
drug classes: Antiarrythmic, Anticoagulants, Anti-thrombotics, Statins and
Beta-blockers, it is generally acknowledged that there are important genetic
variants that significantly influence drug absorption, activation or
metabolism/elimination and should be considered when determining drug
selection, dosing and monitoring. CardioPredict™ represents a new personalized
tool, with proprietary, patent pending features, to help assure that high-risk
cardiovascular patients get the appropriate drug regimen and doses for their
unique personal genetic profile. We believe the clinical value to patients is
significant. There is a large market, a well-defined patient population and a
clearly identified physician base treating these patients that should allow
for a very efficient use of PDI's broad base of commercialization
capabilities."

Conference Call
Date: Today
Time: 9:00 AM (ET)
Dial-in numbers: (866) 644-4654 (U.S. and Canada) or (706) 643-1203
Conference ID#: 83167585
Live webcast: www.pdi-inc.com, under "Investor Relations"

The teleconference replay will be available three hours after completion
through October 19, 2013 at (800) 585-8367 (U.S. and Canada) or (404)
537-3406. The replay pass code is 83167585. The archived web cast will be
available for one year.

About PDI, Inc.

PDI is a leading health care commercialization company providing superior
insight-driven, integrated multi-channel message delivery to established and
emerging health care companies. The company is dedicated to enhancing
engagement with health care practitioners and optimizing commercial
investments for its clients by providing strategic flexibility, full product
commercialization services, innovative multi-channel promotional solutions,
and sales and marketing expertise. For more information, please visit the
company's website at http://www.pdi-inc.com.

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company
advancing personalized medicine in cardiology, oncology, and inherited
diseases. The Company has three complementary business divisions: Clinical
Laboratories, Pharmacogenomic Services and Diagnostic Tools, which provide
specialized diagnostic tests, contract research services for drug development,
and equipment, reagents and other consumables for clinical and research
applications in molecular testing and cytogenetics.

Forward-Looking Statements for PDI

This press release contains forward-looking statements regarding future events
and financial performance. These statements are based on current expectations
and assumptions involving judgments about, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which
are beyond PDI's control. These statements also involve known and unknown
risks, uncertainties and other factors that may cause PDI's actual results to
be materially different from those expressed or implied by any forward-looking
statement. For example, with respect to statements regarding projections of
future revenues, growth and profitability, actual results may differ
materially from those set forth in this release based on the loss, early
termination or significant reduction of any of our existing service contracts,
the failure to meet performance goals in PDI's incentive-based arrangements
with customers, the inability to secure additional business or our inability
to develop more predictable, higher margin business through in-licensing or
other means. Additionally, all forward-looking statements are subject to the
risk factors detailed from time to time in PDI's periodic filings with the
Securities and Exchange Commission, including without limitation, PDI's
subsequently filed Annual Report on Form 10-K for the year ended December 31,
2012 and current reports on Forms 10-Q and Forms 8-K. Because of these and
other risks, uncertainties and assumptions, undue reliance should not be
placed on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may be required
by law, PDI undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.

Forward-Looking Statements for Transgenomic

Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. Forward-looking statements include, but are not
limited to, those with respect to management's current views and estimates of
future economic circumstances, industry conditions, company performance and
financial results, including the ability of the Company to grow its
involvement in the diagnostic products and services markets. The known risks,
uncertainties and other factors affecting these forward-looking statements are
described from time to time in Transgenomic's filings with the Securities and
Exchange Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ materially from
those referred to in such statements. Accordingly, the Company claims the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995 with respect to all
statements contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not undertake
any duty to update this information, including any forward-looking statements,
unless required by law.

SOURCE PDI, Inc.

Website: http://www.pdi-inc.com
Contact: PDI MEDIA AND INVESTOR CONTACT: Melody Carey, Rx Communications
Group, LLC, (917) 322-2571, mcarey@rxir.com; TRANSGENOMIC MEDIA AND INVESTOR
CONTACT: Susan Kim, Argot Partners, (212) 600-1902, susan@argotpartners.com
 
Press spacebar to pause and continue. Press esc to stop.